ArticleDiscover oncology2026
Constructing and investigating a disulfidptosis-associated LncRNA signature for prognostic prediction in gastric cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundGastric cancer (GC) prognosis remains poor, necessitating reliable biomarkers. Disulfidptosis represents a promising therapeutic frontier. This study aimed to construct a prognostic model based on disulfidptosis-related LncRNAs (DRLs) and investigate their function.
methodsDRLs were screened from TCGA-STAD using Pearson correlation and LASSO-COX regression to build a prognostic signature. Its accuracy was evaluated via Kaplan-Meier analysis, time-dependent ROC curves, and decision curve analysis. A key DRL was functionally validated in vitro and in vivo.
resultsWe established a six-DRL signature (AC090809.1, CYP4A22-AS1, AL356417.2, Z94721.2, FP325313.3, ERICH3-AS1) that effectively stratified patients into risk groups with distinct survival (P < 0.05). The risk score was an independent prognostic factor, with robust predictive AUCs for 1-, 2-, and 3-year survival. AL356417.2 was upregulated in GC and linked to poor outcome. Its knockdown inhibited cell viability, induced F-actin depolymerization, increased cystine uptake, and suppressed tumor growth in mice.
conclusionWe developed a novel DRL-based prognostic model and identified AL356417.2 as a functional regulator suppressing disulfidptosis, providing mechanistic insights and a potential therapeutic target for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.